<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972175</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00050920</org_study_id>
    <secondary_id>Pro00050920</secondary_id>
    <nct_id>NCT04972175</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BC LisPram</brief_title>
  <official_title>A Randomized Controlled Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, and Closed-loop Efficacy of BC LisPram Compared to Rapid Insulin in Pump-treated Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Tsoukas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Applied Medical Informatics Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is a 50-hour randomized, open-label, crossover study in an inpatient setting&#xD;
      assessing the safety, pharmacodynamics, pharmacokinetics, and closed-loop efficacy of i) BC&#xD;
      LisPram delivery and ii) rapid insulin delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized to intervention sequences. The first 6 participants will be&#xD;
      randomly allocated to a sequence of three treatments composed of (i) treatment with active&#xD;
      comparator insulin lispro, (ii) treatment with BC LisPram, and (iii) treatment with BC&#xD;
      LisPram (dual wave bolus). The following 10 participants will be randomly allocated to a&#xD;
      sequence of either two or three treatments. Each treatment period will last 50 hours. PK/PD&#xD;
      assessment will be performed under an open-loop system and will be followed by a 24 hour of&#xD;
      closed-loop assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of Pramlintide</measure>
    <time_frame>Breakfast, lunch, dinner from 0 to 4 hours</time_frame>
    <description>Area under the pramlintide concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Insulin</measure>
    <time_frame>Breakfast, lunch, dinner from 0 to 4 hours</time_frame>
    <description>Area under the insulin concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Paracetamol</measure>
    <time_frame>Breakfast and dinner from 0 to 4 hours</time_frame>
    <description>Area under the paracetamol concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Pharmacodynamics</measure>
    <time_frame>Breakfast, lunch and dinner from 0 to 4 hours</time_frame>
    <description>Area under the sensor glucose concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucagon Pharmacodynamics</measure>
    <time_frame>Breakfast and dinner from 0 to 4 hours</time_frame>
    <description>Area under the plasma glucagon concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycaemic episodes</measure>
    <time_frame>0 to 50 hours</time_frame>
    <description>Number of hypoglycaemic episodes during the 0 to 50 hour period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>0 to 50 hours</time_frame>
    <description>Frequency of gastrointestinal symptoms during the 0 to 50 hour period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerability at pump injection site</measure>
    <time_frame>0 to 50 hours</time_frame>
    <description>Local tolerability at pump injection site during the 0 to 50 hour period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse event</measure>
    <time_frame>0 to 50 hours</time_frame>
    <description>Number of adverse events during the 0 to 50 hour period.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Rapid Insulin lispro - Conventional bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will use subcutaneously-delivered rapid insulin (lispro) through pump therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BC LisPram - Conventional bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will use subcutaneously-delivered BC LisPram through pump therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BC LisPram - Dual wave bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will use subcutaneously-delivered BC LisPram through pump therapy. During dual wave bolusing, 50% of the prandial bolus is delivered immediately, and the other 50% delivered over the next 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50-Hour Intervention - Rapid Insulin lispro</intervention_name>
    <description>Subcutaneous-delivery of insulin lispro using pump therapy.</description>
    <arm_group_label>Rapid Insulin lispro - Conventional bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50-Hour Intervention - BC LisPram</intervention_name>
    <description>Subcutaneous-delivery of BC LisPram using pump therapy.</description>
    <arm_group_label>BC LisPram - Conventional bolus</arm_group_label>
    <arm_group_label>BC LisPram - Dual wave bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ≥ 18 years of age.&#xD;
&#xD;
          -  Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1&#xD;
             diabetes is based on the investigator's judgment; C peptide level and antibody&#xD;
             determinations are not needed.&#xD;
&#xD;
          -  Insulin pump therapy for at least 3 months, with daily insulin needs ranging between&#xD;
             30 and 80 U.&#xD;
&#xD;
          -  Most recent HbA1c ≤ 9.5% (over the last two months).&#xD;
&#xD;
          -  Effective birth control in female participants of childbearing potential. Medically&#xD;
             acceptable contraception methods include condom, pills, and intrauterine device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin,&#xD;
             Acarbose, etc....).&#xD;
&#xD;
          -  Current use of glucocorticoid medication.&#xD;
&#xD;
          -  Use of medication that alters gastrointestinal motility.&#xD;
&#xD;
          -  Planned or ongoing pregnancy.&#xD;
&#xD;
          -  Breastfeeding individuals&#xD;
&#xD;
          -  Severe hypoglycemic episode within one month of admission.&#xD;
&#xD;
          -  Severe diabetic ketoacidosis episode within one month of admission.&#xD;
&#xD;
          -  Clinically significant nephropathy, neuropathy or retinopathy as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Recent (&lt; 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac&#xD;
             surgery.&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or their excipients.&#xD;
&#xD;
          -  Allergy to paracetamol (acetaminophen).&#xD;
&#xD;
          -  Other serious medical illness likely to interfere with study participation or with the&#xD;
             ability to complete the trial by the judgment of the investigator.&#xD;
&#xD;
          -  Clinically abnormal significant values for haemato, biochemistry, or urinalysis&#xD;
             screening test as judged by the Principle Investigator for underlying disease.&#xD;
&#xD;
          -  Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks,&#xD;
             not willing to change pump parameters, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Tsoukas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied Medical Informatics Research Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexia Macina</last_name>
    <phone>+1 514-623-2520</phone>
    <email>alexia.macina@affiliate.mcgill.ca</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Applied Medical Informatics Research Inc.</investigator_affiliation>
    <investigator_full_name>Michael Tsoukas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pramlintide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

